[1] |
SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun.
Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
|
[2] |
WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan.
Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
|
[3] |
LI Xinyu, HUANG Xin.
State of clinical application of meloxicam
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
|
[4] |
LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling.
Research progress on the antitumor activity of costunolide
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
|
[5] |
ZHOU Guangchen, LIU Yixi, ZHENG Yun.
Colorectal cancer and microRNA: research progress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
|
[6] |
LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui.
circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
|
[7] |
LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian.
OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
|
[8] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|
[9] |
XIE Yan, LI Cheng, ZHANG Lulu, YU Fei, ZANG Shiming, FU Jingjing, LIU Lu, WANG Feng.
Study on binding of 68Ga-PSMA-I&T to newly diagnosed prostate cancer foci
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1379-1385.
|
[10] |
ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie.
Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
|
[11] |
WANG Ziyuan, SUN Mingyu.
Advances in research on long non-coding RNA in drug resistance of colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
|
[12] |
SHI Lili, LIU Xingan, SHAN Guoyong.
Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
|
[13] |
XU Guofang, GAO Pan, LIU Ping, ZHANG Xiaolei, JING Cui, ZHANG Cuicui, JING Huixia, LI Xiaosu, QI Qi.
Bioequivalence of capecitabine tablets in cancer patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1119-1124.
|
[14] |
LI Rongzhen, MEI Jiazhuan, XIA Yunzhan, JI Jie.
Prognostic factors and safety study of R0 resection colorectal cancer patients received capecitabine based adjuvant chemotherapy in real world
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 704-711.
|
[15] |
QIAO Dawei, LI Yufang, XIAO Yun, JIANG Lishuang, BO Ping.
Research progress of Scutellaria barbata against colorectal cancer and its metastasis mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 332-336.
|